Torres, Tiago https://orcid.org/0000-0003-0404-0870
Galván, Jordi https://orcid.org/0000-0002-2435-2129
Crutchley, Nigel https://orcid.org/0000-0002-8726-9816
Praestegaard, Morten https://orcid.org/0000-0003-2413-791X
Iversen, Lars https://orcid.org/0000-0003-1816-4508
Gisondi, Paolo https://orcid.org/0000-0002-1777-9001
Carrascosa, José Manuel https://orcid.org/0000-0003-4266-0771
Halioua, Bruno https://orcid.org/0000-0002-0823-6750
Bewley, Anthony https://orcid.org/0000-0003-1195-0290
Pinter, Andreas https://orcid.org/0000-0002-1330-1502
Funding for this research was provided by:
Almirall S.A.
Article History
Received: 5 July 2023
Accepted: 2 August 2023
First Online: 23 September 2023
Declarations
:
: Tiago Torres has received honoraria for acting as a consultant and/or as a speaker at events sponsored by AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Leo Pharma, MSD, Novartis, Pfizer, Samsung-Bioepis, Sandoz, and Sanofi. Jordi Galván is an employee of Almirall. Nigel Crutchley, Morten Praestegaard and Lars Iversen are employees of MC2 Therapeutics. Lars Iversen has also served as a consultant and/or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Astra Zeneca, BMS, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, Janssen Cilag, Kyowa, Leo Pharma, MSD, Novartis, Pfizer, Regranion, Samsung, Union Therapeutics, UCB. Paolo Gisondi has been a consultant and/or speaker for Abbvie, Almirall, Amgen, Janssen, Eli Lilly, Novartis, Pierre Fabre, Sanofi and UCB. José Manuel Carrascosa has received honoraria or fees as investigator, speaker, and/or advisor from Pfizer, Sanofi, Lilly, AbbVie, Leo-Pharma, Boehringer-Ingelheim and UCB. Bruno Halioua declares that he has no competing interests. Anthony Bewley has served as a consultant to Abbvie, Almirall, Celgene, Galderma, Janssen, Leo Pharma, Lilly, Novartis, Sanofi and UCB; has participated in advisory boards for Psoriasis Association, Changing Faces, ISG and NES; has received grants from EADV and travel grants from Janssen, Leo and Almirall; has participated in guidelines committees of BAD; is working as an editor for the book Practical Psychodermatology, as president for ESDaP and as a chair for APPGOS. Andreas Pinter has received honoraria as investigator and/or has received speakers’ honoraria and/or has received grants and/or has been an advisor for the following companies: AbbVie, Almirall, Amgen, Biogen Idec, Boehringer-Ingelheim, Celgene, Celltrion, GSK, Eli-Lilly, Galderma, Hexal, Janssen, LEO-Pharma, MC2, Medac, Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Roche, Sandoz Biopharmaceuticals, Sanofi-Genzyme, Schering-Plough, UCB Pharma and Zuellig Pharma.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.